Usefulness of sparfloxacin against Chlamydia pneumoniae infection in patients with bronchial asthma

被引：3

作者：

Horiguchi, T ^{[1
]}

Miyazaki, J ^{[1
]}

Ohira, D ^{[1
]}

Watanabe, Y ^{[1
]}

Hayashi, N ^{[1
]}

Kobayashi, K ^{[1
]}

Torigoe, T ^{[1
]}

Fukumoto, K ^{[1
]}

Ito, T ^{[1
]}

Hirose, M ^{[1
]}

Sasaki, Y ^{[1
]}

Shiga, M ^{[1
]}

Kondo, R ^{[1
]}

Handa, M ^{[1
]}

Tachikawa, S ^{[1
]}

机构：

[1] Fujita Hlth Univ, Dept Resp Internal Med, Training Hosp 2, Nakagawa Ku, Nagoya, Aichi 4548509, Japan

来源：

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH | 2005年 / 33卷 / 06期

关键词：

sparfloxacin; quinolone antibacterial agent; bronchial asthma; antibody titres; asthma symptoms;

D O I：

10.1177/147323000503300609

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The efficacy of sparfloxacin (SPFX) for the control of bronchial asthma was evaluated in 26 patients with suspected Chlamydia pneumoniae infection. Patients were randomly allocated to receive SPFX 200 mg/day (n = 14) or control treatment (n = 12) for 21 days. Significant improvements in serum C-reactive protein levels, and significant decreases in peripheral eosinophil counts, serum eosinophil cationic protein (ECP) and sputum ECP were observed in the SPFX-treated group at day 21. SPFX-treated patients also had a significantly reduced frequency of asthma symptoms, reduced inhalant Beta(2)-stimulant use, and significant increases in morning peak expiratory flow. At the end of the study, C. pneumoniae was undetectable in two SPFX-treated patients who underwent polymerase chain reaction testing, but one control patient who was tested still had detectable levels of C. pneumoniae. These results suggest that SPFX could be used to control bronchial asthma in patients with suspected persistent C. pneumoniae infection.

引用

页码：668 / 676

页数：9

共 17 条

[1] Serological evidence of infection with Chlamydia pneumoniae is related to the severity of asthma [J].

Black, PN ;

Scicchitano, R ;

Jenkins, CR ;

Blasi, F ;

Allegra, L ;

Wlodarczyk, J ;

Cooper, BC .

EUROPEAN RESPIRATORY JOURNAL, 2000, 15 (02) :254-259

[2] Chlamydia pneumoniae and asthma [J].

Cook, PJ ;

Davies, P ;

Tunnicliffe, W ;

Ayres, JG ;

Honeybourne, D ;

Wise, R .

THORAX, 1998, 53 (04) :254-259

[3] Virus-induced airway hyperresponsiveness and asthma [J].

Folkerts, G ;

Busse, WW ;

Nijkamp, FP ;

Sorkness, R ;

Gern, JE .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (06) :1708-1720

[4]

GIL JC, 1993, ANN ALLERGY, V70, P23

[5] ASSOCIATION OF CHLAMYDIA-PNEUMONIAE (STRAIN TWAR) INFECTION WITH WHEEZING, ASTHMATIC BRONCHITIS, AND ADULT-ONSET ASTHMA [J].

HAHN, DL ;

DODGE, RW ;

GOLUBJATNIKOV, R .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (02) :225-230

[6]

KAMESAKI S, 1998, JPN J ALLERGOL, V47, P667

[7]

Kishimoto T, 1996, Kansenshogaku Zasshi, V70, P821

[8]

Kishimoto T, 1996, Kansenshogaku Zasshi, V70, P830

[9]

KUROSAKI T, 2000, SHONIKA, V41, P1286

[10]

*MIN HLTH WELF IMM, 2003, GUID PREV CONTR ASTH

← 1 2 →